Eyeing Opportunity: A Review of Private Equity in Ophthalmology

Private equity (PE) acquisition of ophthalmology practices has grown rapidly, reflecting broader trends in the consolidation of health care services. The driving force behind these acquisitions is the potential for high returns through operational efficiencies, increased bargaining power with insurers, and access to lucrative outpatient procedures. However, PE's impact on the quality and cost of ophthalmic care remains unclear. Studies show mixed results: some report increased use of expensive treatments and higher costs, while others suggest minimal changes in patient outcomes or spending. PE's appeal to ophthalmologists includes capital infusion for practice expansion and improved risk management, though concerns exist over profit-driven incentives possibly compromising patient care. The market for ophthalmology practices remains fragmented, with PE firms capitalizing on consolidation opportunities. Despite the growth, there are challenges to assessing the full impact of PE involvement, particularly due to limited research, nondisclosure agreements, and difficulty in selecting control practices for comparison. While PE acquisitions have been accelerating, recent reports indicate a slowdown in 2024, influenced by factors such as interest rates and federal investigations into the health care sector. The future of PE in ophthalmology will likely depend on market conditions, regulatory changes, and further research into its long-term effects on care quality and physician autonomy.